What Key Growth Drivers Are Shaping The Calcitonin Gene-Related Peptide Receptor Antagonist Market Forecast Toward $3.47911666602423 Billion?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Much Will The Calcitonin Gene-Related Peptide Receptor Antagonist Market Be Worth By 2029?
The market for the antagonist of the calcitonin gene-related peptide receptor has seen fast-paced growth in the recent past. Projected to increase from $2.06 billion in 2024 to $2.30 billion in 2025, the compound annual growth rate (CAGR) is expected to be 11.2%. Factors such as the widening of clinical trials demonstrating effectiveness, acceleration in global healthcare spending, escalated detection rates of migraine disorders, enhanced uptake of preventive migraine treatments, and a robust development pipeline for CGRP antagonist elements have contributed to the historical growth period.
Over the coming years, the market size of the calcitonin gene-related peptide receptor antagonist is predicted to experience a swift rise, with projections indicating a growth to $3.48 billion in 2029 at a compound annual growth rate (CAGR) of 11.0%. This surge during the predicted period can be credited to various elements such as the approval of favorable regulatory measures, an increase in research funding, the growing application of innovative migraine prevention treatments, and a rising geriatric population. Key trends observed within the forecast period encompass the advancement in oral small molecule, the emergence of wearable-triggered dosing mechanisms, the development of long-acting injectable prescriptions, the use of nanoparticle drug movers, and examinations into gene therapy.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25715&type=smp
What Market Forces Are Contributing To The Growth Of The Calcitonin Gene-Related Peptide Receptor Antagonist Market?
The rise in the frequency of migraines is projected to enhance the expansion of the calcitonin gene-related peptide receptor antagonist market. Migraine is characterized by a severe headache, often causing throbbing pain, typically on one side of the head. The surge in migraine occurrences is associated with increasing stress levels due to busy city life, inconsistent sleep patterns, and increased exposure to noise, pollution, and bright lights as the urban population grows. Calcitonin gene-related peptide receptor antagonists aid in migraine relief by obstructing CGRP, a protein that expands blood vessels and sends pain signals during a migraine episode, effectively lessening headache pain and other symptoms. As an example, a study from the National Library of Medicine, a US-based national library, disclosed that a roundabout estimate of 61,204 individuals in the US were identified as having migraines by a medical professional in 2022, a 5.5% rise from 2021. Hence, the growing incidence of migraines is fueling the calcitonin gene-related peptide receptor antagonist market’s expansion.
Which Segments Define The Structure Of The Calcitonin Gene-Related Peptide Receptor Antagonist Market?
The calcitonin gene-related peptide receptor antagonist market covered in this report is segmented –
1) By Type: Small Molecule Antagonists, Monoclonal Antibodies, Peptide-Based Antagonists
2) By Drug Type: Zavegepant, Ubrogepant, Olcegepant, Telcegepant, Rimegepant, Other Drug Types
3) By Application: Migraine Treatment, Pain Management, Cardiovascular Conditions, Bone Disorders
4) By End-Users: Hospitals, Clinics, Homecare Settings, Pharmaceutical Companies
Subsegments:
1) By Small Molecule Antagonists: Oral Small Molecule Antagonists, Intranasal Small Molecule Antagonists, Injectable Small Molecule Antagonists
2) By Monoclonal Antibodies: Erenumab, Fremanezumab, Galcanezumab, Eptinezumab
3) By Peptide-Based Antagonists: CGRP Fragment-Based Antagonists, Peptidomimetic CGRP Antagonists
What Strategic Shifts And Innovations Are Influencing The Calcitonin Gene-Related Peptide Receptor Antagonist Market?
Leading enterprises in the calcitonin gene-related peptide receptor antagonist market are concentrating on achieving endorsements for groundbreaking products such as oral CGRP receptor antagonists designed to bolster the effectiveness of migraine relief, broaden therapeutic applications, and provide preferable routes of administration. Oral CGRP receptor antagonists are essentially tiny molecule drugs that halt CGRP, a protein associated with triggering migraines, thereby preventing them. In an example from April 2023, U.S. biotech firm, AbbVie Inc., obtained U.S. Food and Drug Administration (FDA) consent for QULIPTA (atogepant) as a chronic migraine treatment for adults. Specifically engineered for preventive migraine treatment in adults, QULIPTA (atogepant) is an oral, once-daily calcitonin gene-related peptide (CGRP) receptor antagonist that now has approval for both episodic and chronic migraines in America. This medicine operates by inhibiting CGRP, a protein that typically surges during migraine assaults and influences pain transmission and inflammation in the brain. QULIPTA comes in tablet strengths of 10 mg, 30 mg, and 60 mg, with the 60 mg dosage precisely assessed for the prevention of chronic migraines.
Which Firms Are Making The Biggest Impact In The Calcitonin Gene-Related Peptide Receptor Antagonist Market?
Major companies operating in the calcitonin gene-related peptide receptor antagonist market are Pfizer Inc., Merck & Co. Inc. , AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Sosei Group Corporation, Teva Pharmaceutical Industries Ltd., UCB S.A., Alder BioPharmaceuticals, Inc. , H. Lundbeck A/S, Otsuka Pharmaceutical Co. Ltd., Biosynth Carbosynth , Seurat Therapeutics Inc., Satsuma Pharmaceuticals Inc., Allergan plc , Brise Pharmaceutical (Shanghai) Co Ltd., Nuvie Biopharma Inc.
Access The Complete Report Here:
Which Region Is Forecasted To Lead The Calcitonin Gene-Related Peptide Receptor Antagonist Market In The Coming Years?
North America was the largest region in the calcitonin gene-related peptide receptor antagonist market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calcitonin gene-related peptide receptor antagonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25715&type=smp
Browse Through More Reports Similar to the Global Calcitonin Gene-Related Peptide Receptor Antagonist Market 2025, By The Business Research Company
Peptide And Oligonucleotide Cdmo Global Market Report 2025
Peptide Based Metabolic Disorders Therapeutics Global Market Report 2025
Muscarinic Acetylcholine Receptor Global Market Report 2025
About The Business Research Company:
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
